Who are DLBS3233's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Z. officinale extract, Centella asiatica, Arnica Tincture.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dlbs3233.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DLBS3233 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DLBS3233 (DLBS3233) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal extract / Natural product. Area: Hepatology / Gastroenterology.

phase 3 Herbal extract / Natural product Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

DLBS3233 (DLBS3233) — Dexa Medica Group. DLBS3233 is a bioactive fraction derived from Cinnamomum burmannii that modulates lipid metabolism and reduces hepatic steatosis through multiple pathways.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
DLBS3233 TARGET	DLBS3233	Dexa Medica Group	phase 3	Herbal extract / Natural product
Z. officinale extract	Z. officinale extract	Fundação Educacional Serra dos Órgãos	marketed	Herbal extract / Natural product
Centella asiatica	Centella asiatica	Başakşehir Çam & Sakura City Hospital	marketed	Herbal extract / Natural product
Arnica Tincture	Arnica Tincture	Universidad de Antioquia	phase 3	Herbal extract / Natural product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal extract / Natural product class)

Başakşehir Çam & Sakura City Hospital · 1 drug in this class
Dexa Medica Group · 1 drug in this class
Fundação Educacional Serra dos Órgãos · 1 drug in this class
Universidad de Antioquia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DLBS3233 — Competitive Intelligence Brief. https://druglandscape.com/ci/dlbs3233. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing